Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Wave Life Sciences (WVE) Gains from Investment Securities (2014 - 2022)

Wave Life Sciences posted quarterly Gains from Investment Securities of -$12.0 million for Q4 2022, down 569.27% on a QoQ basis from $2.6 million in Q3 2019.

Wave Life Sciences (WVE) has 7 years of Gains from Investment Securities data on file, last reported at -$12.0 million in Q4 2022.

  • For the quarter ending Q4 2022, Gains from Investment Securities changed N/A year-over-year to -$12.0 million; the trailing twelve-month figure through Dec 2022 stood at -$7.1 million (changed N/A YoY), and the FY2022 full-year result was -$12000.0, down 100.27% from the prior year.
  • Gains from Investment Securities for Q4 2022 stood at -$12.0 million, down from $2.6 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $2.6 million in Q1 2019 and bottomed at -$12.0 million in Q4 2022.
  • The 3-year median for Gains from Investment Securities is $8000.0 (2018), against an average of -$574125.0.
  • The widest annual swing landed in 2018, when Gains from Investment Securities plunged 100.55%; it then soared 233200.0% in 2019.
  • A 3-year view of Gains from Investment Securities shows it stood at -$59000.0 in 2018, then surged by 4440.68% to $2.6 million in 2019, then slumped by 569.27% to -$12.0 million in 2022.
  • The last three Gains from Investment Securities figures came in at -$12.0 million (Q4 2022), $2.6 million (Q3 2019), and $2.3 million (Q2 2019), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn -
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn -
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn
7 Evaxion A 64.16 Bn 64.14 Bn -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn
10 Wave Life Sciences 1.32 Bn 772.50 Mn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2022 -12.02 Mn
Dec 31, 2022 -12.02 Mn
Sep 30, 2019 2.56 Mn
Sep 30, 2019 2.56 Mn
Jun 30, 2019 2.33 Mn
Jun 30, 2019 2.33 Mn
Mar 31, 2019 2.58 Mn
Mar 31, 2019 2.58 Mn
Dec 31, 2018 -59,000.00
Dec 31, 2018 -59,000.00
Sep 30, 2018 5,000.00
Sep 30, 2018 5,000.00
Jun 30, 2018 -1,000.00
Jun 30, 2018 -1,000.00
Mar 31, 2018 11,000.00
Mar 31, 2018 11,000.00
Dec 31, 2017 -416,000.00
Dec 31, 2017 -416,000.00
Sep 30, 2017 11,000.00
Sep 30, 2017 11,000.00
Jun 30, 2017 182,000.00
Jun 30, 2017 182,000.00
Mar 31, 2017 18,000.00
Mar 31, 2017 18,000.00
Dec 31, 2016 501,000.00
Dec 31, 2016 501,000.00
Jun 30, 2016 3.15 Mn
Jun 30, 2016 3.15 Mn
Mar 31, 2016 53,000.00
Mar 31, 2016 53,000.00
Dec 31, 2015 2.22 Mn
Dec 31, 2015 2.22 Mn
Sep 30, 2015 1.94 Mn
Sep 30, 2015 1.94 Mn
Mar 31, 2015 547,502.00
Mar 31, 2015 547,502.00
Dec 31, 2014 -7,000.00
Dec 31, 2014 -7,000.00